Promising Healthcare Stocks Worth Watching - November 3rd

Key Points

• MarketBeat identified seven healthcare stocks to watch: Eli Lilly, Moderna, Natera, CVS Health, Pfizer, Vertex Pharmaceuticals, and Johnson & Johnson, selected based on recent trading volume.
• Eli Lilly and Moderna posted notable gains during Tuesday trading, reaching $1,419.96 and $232.15, respectively; Lilly’s market capitalization stood at approximately $1.34 trillion.
• The group spans pharmaceuticals, biotechnology, diagnostics, healthcare services, and medical devices, offering exposure to areas such as obesity treatments, vaccines, genetic testing, chronic disease therapies, and healthcare benefits—but remains subject to regulatory, approval, litigation, and reimbursement risks.

Eli Lilly and Company, Moderna, Natera, CVS Health, Pfizer, Vertex Pharmaceuticals, and Johnson & Johnson are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in the healthcare industry, including pharmaceuticals, biotechnology, medical devices, hospitals, health insurers, and healthcare services. For investors, these stocks may offer growth opportunities driven by medical innovation and demographic trends, but they can also be affected by regulatory changes, drug approvals, litigation, and reimbursement policies. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Eli Lilly and Company stock traded up $8.97 during midday trading on Tuesday, hitting $1,419.96. 1,040,120 shares of the stock were exchanged, compared to its average volume of 2,938,932. The stock has a market capitalization of $1.34 trillion, a PE ratio of 46.12, a P/E/G ratio of 1.73 and a beta of 0.40. The company has a fifty day simple moving average of $1,200.81 and a two-hundred day simple moving average of $1,094.25. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,449.68.

Read Our Latest Research Report on LLY

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

NASDAQ:MRNA traded up $11.31 during trading hours on Tuesday, hitting $232.15. The stock had a trading volume of 5,182,469 shares, compared to its average volume of 12,606,107. The business's 50 day moving average is $184.00 and its 200-day moving average is $87.42. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market cap of $92.68 billion, a price-to-earnings ratio of -29.03 and a beta of 1.09. Moderna has a one year low of $22.28 and a one year high of $254.48.

Read Our Latest Research Report on MRNA

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Shares of NTRA stock traded up $9.84 on Tuesday, hitting $388.76. The stock had a trading volume of 2,084,737 shares, compared to its average volume of 1,413,963. Natera has a twelve month low of $181.00 and a twelve month high of $437.41. The firm has a market cap of $56.04 billion, a P/E ratio of -286.10 and a beta of 1.55. The company has a fifty day moving average price of $378.00 and a two-hundred day moving average price of $267.14.

Read Our Latest Research Report on NTRA

CVS Health (CVS)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

CVS Health stock traded up $1.54 during mid-day trading on Tuesday, hitting $90.05. 8,447,140 shares of the company's stock were exchanged, compared to its average volume of 8,281,662. CVS Health has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $115.18 billion, a P/E ratio of 23.81, a PEG ratio of 0.84 and a beta of 0.60. The company's 50 day simple moving average is $91.13 and its 200-day simple moving average is $88.80.

Read Our Latest Research Report on CVS

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Shares of NYSE PFE traded down $0.24 during mid-day trading on Tuesday, reaching $30.43. 22,310,020 shares of the company's stock were exchanged, compared to its average volume of 39,636,875. The firm has a market capitalization of $173.42 billion, a price-to-earnings ratio of 40.03, a PEG ratio of 2.00 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $28.60 and a 200 day simple moving average of $26.82. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.06.

Read Our Latest Research Report on PFE

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of NASDAQ:VRTX traded down $18.52 during trading on Tuesday, hitting $534.62. 1,204,990 shares of the company's stock traded hands, compared to its average volume of 1,388,479. The company has a 50-day moving average price of $523.32 and a 200-day moving average price of $479.96. Vertex Pharmaceuticals has a 52 week low of $403.16 and a 52 week high of $568.67. The company has a market cap of $135.69 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.54 and a beta of 0.28.

Read Our Latest Research Report on VRTX

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

NYSE JNJ traded down $3.02 during trading hours on Tuesday, reaching $267.54. 1,996,987 shares of the company's stock were exchanged, compared to its average volume of 7,933,802. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market capitalization of $644.06 billion, a price-to-earnings ratio of 40.58, a price-to-earnings-growth ratio of 2.68 and a beta of 0.22. The company's 50-day moving average is $265.74 and its two-hundred day moving average is $247.22. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02.

Read Our Latest Research Report on JNJ

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.